A phase I satri-cel report described durable peritoneal disease control in advanced gastric cancer patients with peritoneal metastasis. In trial NCT03874897, three patients with confirmed high claudin 18.2 expression achieved ongoing peritoneal responses after infusion of satri-cel. The report highlights that all three patients had verified clinical and radiologic benefit. The case narratives include one patient who went on to conversion surgery eight months after infusion, followed by resection of bilateral ovarian metastases and long-term peritoneal control. While early and based on a small cohort, the durability and peritoneal focus are notable in a setting where systemic treatment options for peritoneal spread have been limited.